The COL-4A1 polypeptide destroy endothelial cells through the TGF-β/PI3K/AKT pathway

Ting Li¹,², Zhonghui Ling¹,², Kaipeng Xie¹, Yixiao Wang¹, Zhijing Miao¹, Xiaohong Ji³, Jingyun Li¹, Wenwen Hou¹, Qiuqin Tang¹, Xiaojie Yuan¹, Nan Li¹, Chanjuan Li¹,², & Hongjuan Ding¹

Preeclampsia (PE) is commonly considered as a placental disorder in pregnancy. Until now, the etiology and pathological mechanism of PE have remained ambiguous. Although PE can lead to a variety of maternal and infant complications, there are still no effective treatments. This study aimed to explore the correlation between the novel polypeptide COL-4A1 and PE, and to identify the underlying mechanism by which this polypeptide may function and to explore new therapeutic targets for PE. A rat model of PE was established and used to verify the function of the polypeptide COL-4A1 in vivo. Additionally, human umbilical vascular endothelial cells (HUVECs) were cultured with or without COL-4A1 and TNF-α (20 ng/ml). Cell Counting Kit-8 (CCK-8), wound-healing, Transwell and tube formation assays were used to evaluate cell proliferation, migration and angiopoiesis. RNA sequencing and mass spectrometry were conducted to explore the underlying downstream mechanism of COL-4A1. In vivo, COL-4A1 increased blood pressure and elevated the risk of fetal growth restriction (FGR) which was induced by lipopolysaccharide (LPS) in the rat model. In vitro, COL-4A1 significantly inhibited the proliferation and migration of HUVECs. After culture with COL-4A1, compared to control group the adhesive ability and level of reactive oxygen species (ROS) were enhanced and tube formation ability was decreased. Furthermore, Western blotting (WB) and pull-down assays were conducted to explore the underlying mechanism by which COL-4A1 functions, and the TGF-β/PI3K/AKT pathway was identified as the potential pathway involved in its effects. In summary, these results revealed that the polypeptide COL-4A1 caused PE-like symptoms in cells and a rat model. Through the TGF-β/PI3K/AKT pathway, COL-4A1 interferes with the pathogenesis of PE. Thus COL-4A1 is expected to become a potential target of PE, providing a basis for exploring the treatment of PE.

Preeclampsia (PE), a common complication and multiorgan disorder during pregnancy, is commonly considered as a placental disorder and affects 5–8% of pregnant women. After 20 weeks gestation, women with PE experience hypertension with or without proteinuria and renal, liver or neurological organ dysfunction, or fetuses experience with fetal growth restriction (FGR). PE is also one of the highest causes of morbidity and mortality in pregnant women and leads to a variety of short-term and long-term complications in mothers and infants, including cardiovascular diseases, renal disease, metabolic disorders, placental abruption, FGR, and preterm birth. Early prediction of PE is still lacking, and diagnosis is mainly based on clinical symptoms. However, although antihypertensive drugs and therapeutic labor induction can alleviate the symptoms of PE, there are still no effective treatments for PE. Therefore, to explore the mechanism and target of PE, and to search for a new effective treatment has always been a research topic in this field.

Until now, the etiology and pathological mechanism of PE have remained ambiguous. Studies have shown that genetics, oxidative stress, inflammation, immune and environmental factors are related to the PE, which has been described with the two-stage placental model theory. Numerous reports have suggested that placental factors are the main factors in the pathogenesis of PE. For example, disorder of trophoblast cell

¹Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing, China. ²These authors contributed equally: Ting Li and Zhonghui Ling. ³email: annels@163.com; njdinghj@163.com
migration and invasion resulted in shallow placental implantation. Insufficient uterine spiral artery remodelling led to narrow vessels, placental ischaemia, hypoxia and vascular endothelial damage. At the same time, some inflammatory factors and angiogenic factors, such as tumour necrosis factor α (TNF-α) and endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), placental growth factor (PIGF), and soluble fms-like tyrosine kinase-1 (sFlt-1), are released into the maternal blood circulation, which ultimately caused the mother developing PE.

Recently, polypeptides have become a research focus in therapeutics. Information regarding the potential effects of peptides on PE remains ambiguous and scant. With the development of polypeptide omics and progress in mass spectrometry, our team screened serum polypeptides from healthy controls and PE patients through liquid chromatography-tandem mass spectrometry (LC–MS/MS), and found that the collagen alpha-1 (IV) chain was significantly up-regulated in patients with PE. We named this polypeptide COL-4A1. There have been some reports about the precursor proteins of COL-4A1. In 1997, collagen IV was firstly found to be related to the proliferation and differentiation of cells in the maternal stroma. In 2003, a study indicated that collagen IV is associated with the migration of trophoblast cells in bovine placentomes. Some studies have shown that collagen IV is related to angiogenesis and cell proliferation. In 2018, a review summarized the increasing evidence indicating the role of the collagen alpha-1 (IV) chain in cardiovascular disease (CVD), and proteomic analysis revealed increased collagen type IV in the nonatherosclerotic arteries of patients with type 2 diabetes, but the mechanism is unknown. Although there are some studies on precursor proteins of COL-4A1, the function of the polypeptide is still unclear. Moreover, researches on the function and underlying mechanisms of the polypeptide COL-4A1 in PE remain scant. In the current study, we used an animal model and cell culture to explore the correlation between the novel polypeptide COL-4A1 and PE. And to uncover its underlying mechanism for the development of new therapeutic strategies for PE.

Material and methods

The peptide. The biological macromolecule of COL-4A1 polypeptide consists of a 7-amino-acid sequence (ILGHVPG) and its molecular weight is 2562.02 kDa. Because of the low lipophilicity and weak alkalinity of COL-4A1, we linked a cell-penetrating peptide derived from the HIVTAT sequence (Ac-GRKKRRQRRRPQQ, Biotin-GRKKRRQRRRPPQQ: for pull-down) to its N terminus. The COL-4A1 polypeptide we used in the present study was synthesized by Shanghai Science Peptide Biological Technology Co., Ltd., and its purity was >95%. The COL-4A1 polypeptide was dissolved in water to obtain the diluted peptide at different concentrations.

Animals experimental protocol. All animal experiments were conducted following the guidelines of the Institutional Animal Care Committee and experiments were carried out in compliance with the ARRIVE guidelines. The animal experimental protocols were approved by the Nanjing Medical University Animal Ethics Committee (Approval approval No.: 2005040). Sprague–Dawley (SD) rats (10–12 weeks old, 200–250 g) were purchased from the Experimental Animal Center of Vitol Lihua Co., Ltd. According to previous studies, the injection of LPS (Sigma, USA) into rats can cause PE-like symptoms, forming a PE rat model. The rats were raised in a light-, humidity- and temperature-controlled environment with free access to food and water under specific pathogen-free (SPF) conditions at the Department of Nanjing Yutong Biotechnology Co., Ltd. After 1 week of acclimatization, vaginal smears for sperm were performed in the morning after females had been housed overnight with a fertile male at a 2:1 ratio. Positive vaginal smears confirmed pregnancy and were used to designate day 0 of pregnancy (gestational day 0, GD 0). On GD 0, pregnant rats were randomly separated into 3 groups: group 1 (saline) (n = 6), group 2 (PE) (n = 6) and group 3 (PE + the COL-4A1 polypeptide) (n = 6). On GD 5 and GD 7, group 1 rats received saline (1.0 mg/kg) via the tail vein, group 2 rats were treated with lipopolysaccharide (LPS) (1.0 µg/kg) (Sigma Aldrich, USA) via the tail vein, and group 3 (PE + the COL-4A1 polypeptide) rats were pretreated with LPS (1.0 µg/kg) via the tail vein. Then, the rats in group 3 were intraperitoneally (ip) administered COL-4A1 (5 mg/kg) on GD 11, GD 14 and GD 17. On GD 20, the rats were euthanized; blood samples were obtained from the inferior cava vena. Serum was stored at −80 °C for subsequent analysis. Urine samples were collected from the rats and rats were fasted but free to drink water in standard rat metabolic cages. Urine protein and urine creatinine levels were measured using a urine protein quantitation kit (C035-1, Nanjing, China) and creatinine assay kit (C011-2-1, Nanjing, China), respectively.

Blood pressure and urinary protein levels. Systolic blood pressure (SBP) was monitored with a Non-invasive Volume Pressure Recording (VPR) Blood Pressure-monitoring Tail-cuff Plethysmograph (Softron, Japan) on GD 4, 7, 11, 15 and 19. Ten measurements were taken from each rat at a time. On GD 19, 24-h urine samples were collected from the rats and rats were fasted but free to drink water in standard rat metabolic cages. Urine samples were centrifuged at 2000 rpm for 15 min at room temperature, and supernatants were stored at −80 °C for subsequent analysis. Urine protein and urine creatinine levels were measured using a urine protein quantitation kit (C035-1, Nanjing, China) and creatinine assay kit (C011-2-1, Nanjing, China), respectively.

Cell culture. HUVECs were purchased from American Type Culture Collection (ATCC, USA). They were cultured in DMEM (GIBCO, USA) with 10% fetal bovine serum (FBS) (GIBCO, USA) and 100 U/ml penicillin and 100 µg/ml streptomycin (GIBCO). HUVECs were used for experiments when cultured in the third to sixth generation. The cells were maintained in a humidified incubator at 37 °C with 5% CO2 and 95% O2.

Cell counting Kit-8 assay (CCK-8) for cell proliferation. HUVECs cells were seeded into 96-well plates at 3 × 103 per well. Cells were treated with or without COL-4A1 and TNF-α (20 ng/ml). A CCK-8 cytotoxicity assay (Dojindo, CK04-13, Japan) was used to evaluate the proliferative capacity of the HUVECs. After the cells had attached, according to the manufacturer’s instructions, we added 10 µl of CCK-8 solution to the medium.
and then incubated the cells at 37 °C and 5% CO₂ for 2 h. Finally, a multifunctional microplate reader was used to record the cell OD value at 450 nm at 0 h (Hybrid Technology, BioTek, USA). Additionally, we recorded the cell OD values at 24 h, 48 h and 72 h. The experiments were conducted with triplicate samples and repeated three times.

**Wound-healing assay and Transwell assay of migration.** HUVECs migration was assessed by wound-healing and Transwell assays, and the differences among cells treated with different concentrations of COL-4A1 (0 μM, 30 μM) were compared. Wound-healing assay: When the cells were full covered in a six-well plate, a 100-μl tip was used to scratch a straight line through the middle of each well. Then, we used PBS (GIBCO, USA) washing to remove necrotic cells 3 times, after which the cells were cultured in serum-free DMEM; this time point was set as 0 h. We photographed the scratch width per well at 0 h and 48 h. The following ratio was used to reveal the wound healing rate: (scratched area at 0 h – scratched area at 48 h)/scratched area at 0 h. Transwell assay: In the upper chambers of the wells of a Transwell plate (3428, Corning, USA), a total of 5 × 10⁴ cells was seeded with 200 μl of serum-free DMEM. To the lower chambers, we added 700 μl of DMEM containing 20% FBS. After 36 h of incubation at 37 °C with 5% CO₂, we processed the Transwell chamber by the addition of 700 μl of paraformaldehyde (4%) at 4 °C for 30 min to fix the cells and 700 μl of 1% crystal violet to stain the cells for 30 min in the dark, after which noninvaded cells in the upper chamber were removed with a cotton swab. We randomly selected and photographed three different fields, and images were captured at 100× magnification with a ZEISS inverted microscope (ZEISS, Germany). The migrated cells were counted, and the average value was recorded. The experiments were repeated three times.

**In vitro tube formation assay.** HUVECs were cultured with different concentrations of COL-4A1 (0 μM, 30 μM) and TNFα (20 ng/ml) at 37 °C and 5% CO₂ for 24 h. A 48-well cell culture plate was coated with 100 μl/well undiluted Matrigel basement membrane matrix (Corning 356234, USA) and incubated at 37 °C for 30 min to allow the Matrigel to coagulate. Cells in the control group and those treated with COL-4A1 (30 μM) as described above were collected. The HUVECs were counted with a counting chamber (Life Technology, USA), and 8 × 10⁴ cells per well were seeded on wells coated with Matrigel ²₈. Three replicate wells were set per group, and the cells were incubated for 16–20 h at 37 °C under 5% CO₂ to allow tube formation. The angiogenesis status was assessed, and images were captured at 100× magnification using a ZEISS inverted microscope (ZEISS, Germany). The experiments were repeated three times.

**Reactive oxygen species (ROS) assay.** A Reactive Oxygen Species Assay Kit (ROS Assay Kit, Yaezen, China) was used with 2,7-dichlorofluorescin-diacetate (DCFH-DA) to detect intracellular ROS levels. Cells were incubated with an appropriate volume of 10 μM DCFH-DA diluted in serum-free DMEM at 1:1000 for 30 min at 37 °C in the dark. Then, serum-free DMEM was used to wash the cells three times to remove the DCFH-DA that had not entered the cells. Finally, the samples were directly observed and photographed at 100× magnification with a laser confocal microscope (ZEISS, Germany). A fluorescence microplate reader (Hybrid Technology, BioTek, USA) was used to detect the fluorescence intensity of each sample; the excitation wavelength was 488 nm, and the emission wavelength was 525 nm. All samples were analyzed in triplicate, and the experiment was repeated three times.

**Monocyte adhesion assay.** HUVECs were seeded in 96-well plates at 1 × 10⁴/well and pretreated with or without COL-4A1 and TNF-α (20 ng/ml) for 24 h. According to the manufacturer’s instructions, THP-1 cells (1 × 10⁶ cells/ml) were stained with calcine-AM (AAT BioQuest, USA) for 1 h at 37 °C with 5% CO₂. Then, the stained THP-1 monocytes (200 μl/well) were added to co-incubate with HUVECs for 1 h at 37 °C with 5% CO₂ and washed three times with PBS to wash away the unadhered THP-1 monocytes. Images were captured at 100× magnification with a ZEISS fluorescence microscope (ZEISS, Germany). The assay was repeated three times.

**RNA isolation and quantitative reverse transcription polymerase chain reaction (qRT-PCR).** TRIzol (700 μl) reagent (Invitrogen Inc., Carlsbad, CA, USA) was used to extract total RNA from samples, and a RevertAid First Strand cDNA Synthesis Kit (Thermo, USA) was used to synthesize cDNA. The concentration and purity of the extracted RNA and cDNA were detected using NanoDrop technology (Agilent, Santa Clara, CA, USA). According to the manufacturer’s instructions, cDNA, ddH2O, primers (TaqMan Gene Expression Assays, Applied Biosystems) and SYBR Green (Thermo, USA) were added to 384-well plates and further processed in a ViiA7 Real-time PCR System from Life Technologies (Applied Biosystems, USA). All primers used for amplification are shown in Table 1. GAPDH was used to normalize all gene expression results. The 2−∆Ct method was used to calculate the gene expression fold changes.

**RNA sequencing.** We isolated total RNA from HUVECs in 6-well plates treated with COL-4A1 (0 μM, 30 μM) for 24 h with three replicates per group. The purity was assessed and RNA single-cell sequencing of each sample was conducted with the free online Majorbio Cloud Platform (Shanghai Majorbio Bio-pharm Technology Co., Ltd). We also performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (KOBAS, Version 2.1.1, http://kobas.cbi.pku.edu.cn/download.php). Additionally, a Venn diagram, volcano plot and heatmap were prepared (edgeR, Version 0.46.0, http://bioconductor.org/packages/stats/bioc/edgeR/).
Pull-down assays and mass spectrometry assays. According to the instructions, we firstly took out 30 μl beads and put them into a 5 ml centrifuge tube (Invitrogen, 00875123). Firstly, we used the lysate (RIPA buffer, Beyotime Institute of Biotechnology, China) to wash the beads for 3 times. Then biotin-COL-4A1 (0 μM, 30 μM) were added to the 5 ml centrifuge tube and incubated with beads overnight at 4 °C. Then, the beads were washed another 6 times the protein sample was added and mixed and the beads were incubated overnight at 4 °C. The polypeptide-protein mixture was mixed with loading buffer and subjected to WB to obtain protein expression data. Finally, we performed silver staining to obtain the differential protein fragments and sent them to a company for mass spectrometry assays (BGI, China).

Western blotting (WB). WB was used to quantify protein levels in the samples. HUVECs were treated with COL-4A1 (0 μM, 30 μM) for 24 h. Proteins were extracted using RIPA buffer, PMSF (Beyotime Institute of Biotechnology, China) and phosphatase inhibitors (Servicebio, Wuhan). The protein samples were then separated by 10% SDS-PAGE (Servicebio, Wuhan) and transferred to nitrocellulose membranes. Then, the membranes were blocked with 5% skim milk (Guangzhou Saiguo Biotech Co., LTD) for 2 h and incubated with beads overnight at 4 °C. Then, the beads were washed another 6 times the protein sample was added and mixed and the beads were incubated overnight at 4 °C. The polypeptide-protein mixture was mixed with loading buffer and subjected to WB to obtain protein expression data. Finally, we performed silver staining to obtain the differential protein fragments and sent them to a company for mass spectrometry assays (BGI, China).

Table 1. Primer sequence for qRT-PCR.

| Gene name | Forward primer (5′-3′) | Reverse primer (5′-3′) |
|-----------|------------------------|-----------------------|
| VEGF      | AGGTGCGCTTTTTCAGGAAAA  | TCCAGGGTGTTGTCAGGAAAA |
| PI GF     | GAGCCACAGACTGCAAC      | ACCGTGCGCAAAGAACAA    |
| sFL T-1   | TTTGCTGAAATGGAGGTAAGG  | TGGTTGCTGAGCTGTTGTC   |
| IC AM-1   | CAATGTTGCTATTCACCAGG   | CAGCGTAAAGTGAAGTTCTT  |
| VCAM-1    | CAAAAGGCTGAGTACGCAAAC  | ACAAGATTTCGGAGGAGG    |
| GAPDH     | GGACGGAAGATCCCTCACAAT  | GGCCTGTGTCATCTTCATGG  |

Figure 1. COL-4A1 aggravated PE-like symptoms in a rat model treated with or without LPS. (A) The SBP of the control (saline) (n = 6), LPS (PE) (n = 6) and LPS + COL-4A1 (PE + COL-4A1) (n = 6) groups was evaluated on GD 4, 7, 11, 15, and 19. (B) Graph showing BP fluctuations in the model rats. (C, D) Images of the placenta and pup and their weights in each group. (E) Kidney and placenta sections from each group were subjected to HE staining. (F) Urinary albumin levels on GD 19. LPS lipopolysaccharide, SBP systolic blood pressure, GD gestational day, PE preeclampsia. (*P < 0.05, **P < 0.01, ***P < 0.001).
Vol.:(0123456789)

**Results**

**COL-4A1 increased blood pressure and the risk of FGR and other PE-like symptoms of in a rat model.** According to the LPS-induced PE-like symptoms, we established an in vivo rat model. As shown in Fig. 1A,B, we observed that the systemic blood pressure (SBP) of the control group (saline, group 1) was essentially unchanged (88.9–90.0 mmHg). In rats that were injected with LPS (group 2), the SBP was significantly increased from GD 11 \( (P < 0.001) \). In group 3 (LPS + COL-4A1), SBP was also elevated from GD 11, and after GD 15, the difference in SBP was significant (109.4 ± 0.4 mmHg group 2 vs 125.9 ± 1.8 mmHg group 3, \( P < 0.05 \)). As shown in Fig. 1C,D, the placental and pup weights of groups 2 and 3 were decreased compared with those of group 1 (All \( P < 0.001 \)). Compared to those of group 2, the placental (0.78 ± 0.01 group 2 vs 0.60 ± 0.02 group 3, \( P < 0.001 \)) and pup weights (4.61 ± 0.16 group 2 vs 3.46 ± 0.17 group 3, \( P < 0.001 \)) of group 3 were further decreased. PE can cause pathological changes in the kidney and placenta, and our results were consistent with this finding. Compared to the control group, both group 2 and group 3 showed oedema and inflammatory changes in the kidney and inflammatory cell infiltration and fibrin deposition in the placenta (Fig. 1E). Through analysis of the rat urine, we obtained urine proteins and found their levels to be elevated in groups 2 and 3 (\( P_{\text{LPS}} < 0.001 \), \( P_{\text{LPS+COL-4A1}} < 0.05 \), Fig. 1F).

**The proliferation and migration of HUVECs were significantly inhibited by COL-4A1.** Based on our *in vivo* PE-like rat model results, we further evaluated proliferation and migration using an *in vitro* cell model.
CCK-8 assays were used to measure the proliferation ability. As Fig. 2A shows, regardless of whether TNF-α had been added, the results were consistent and showed that COL-4A1 inhibited proliferation \((P<0.001, P<0.01)\).

Wound-healing and Transwell assays were performed to detect the ability of the HUVECs to migrate. Compared to the control and control + TNF-α groups, in the COL-4A1 and COL-4A1 + TNF-α groups the ability to migrate in the wound-healing and Transwell assays were inhibited (all \(P<0.001\), Fig. 2B–E).

Effects of COL-4A1 on tube formation, the levels of ROS, and adhesion. Considering the correlation between COL-4A1 and the ability of HUVECs to form tubes, we further performed an in vitro experiment to simulate PE. COL-4A1 inhibited tube formation compared with that in the control group. Moreover, we added TNF-α to simulate PE, and the results were consistent (Fig. 3A). Similarly, we detected the levels of ROS and adhesive ability under both conditions (with or without TNF-α), and the results are depicted in Fig. 3B,C. The image clearly shows that COL-4A1 further elevated the levels of ROS and adhesive ability.

The results of qRT-PCR and RNA sequencing. We detected VEGF, PIGF, sFLT-1, ICAM-1 and VCAM-1 mRNA expression, and the results are shown in Fig. 4A. The expression levels of VEGF and PIGF were decreased in the COL-4A1 group \((P<0.001)\). However, compared to those in the control group, sFLT-1 \((P<0.001)\), ICAM-1 \((P<0.05)\) and VCAM-1 \((P<0.05)\) mRNA expression levels were elevated in the COL-4A1 group. To further understand the mechanism of COL-4A1, transcriptome sequencing of RNA from HUVECs in the control and COL-4A1 group were performed. Heatmap revealed that differential genes which were detected with and without COL-4A1 treatment \((P<0.05, \text{fold change}=2)\,\text{Fig. 4B}\). Moreover, we further analyzed the differentially expressed genes through a volcano plot (Fig. 4B) and we found more down-regulated genes than up-regulated genes in the COL-4A1 vs control group \((321 \text{ vs } 209)\). To further understand the potential mechanism of COL-4A1, GO and KEGG analysis were conducted. GO analysis showed that the genes are mainly focused on the “regulation of biological quality” pathway (Fig. 4D). The TGF-β signalling pathway has been reported to inhibit HTR-8/SVneo cell and HUVECs proliferation, migration, invasion and tube formation\(^{30}\). KEGG analysis also showed that the TGF-β signalling pathway may be the pathway by which COL-4A1 functions (Fig. 4E).

The results of pull-down assays and mass spectrometry assays. To further explore the pathway by which polypeptide COL-4A1 function, biotin COL-4A1 was synthesized for pull-down assays in which several differing protein fragments were obtained (Fig. 5A). Additionally, a Venn diagram of the mass spectrometry results indicated 97 proteins whose expression differed between the control and COL-4A1 groups (Fig. 5B). Furthermore, a potential protein polymerization pathway map was constructed (Fig. 5C). The classic PI3K-
AKT pathway was included in this map ($P < 0.05$). Some reports have stated the pathway PI3K/AKT, which may contribute to the pathology of PE. For example, PI3K/AKT pathway plays a key role in cell metabolism and proliferation, inhibiting tube formation and mediating inflammatory processes.\textsuperscript{27,31}

The underlying mechanism by which COL-4A1 may function. Based on our results of RNA sequencing and mass spectrometry analysis, and we searched for the functions of the associated proteins with both GO and KEGG pathway analysis. Furthermore, the TGF-β signalling pathway was reported to inhibit HTR-8/SVneo cell and HUVECs proliferation, migration, invasion and tube formation.\textsuperscript{30} Additionally, some reviews have reported that PI3K/AKT, which may contribute to the pathology of PE, plays a key role in cell metabolism and proliferation, inhibiting tube formation and mediating inflammatory processes.\textsuperscript{27,31} Hence, we hypothesized that COL-4A1 functions through the TGF-β/PI3K/AKT pathway. Then, we verified this hypothesis by pull-down and WB assays. Based on Fig. 5D,E, the protein expression of TGF-β was decreased ($P < 0.01$), but PI3K expression and the p-AKT/AKT ratio were increased ($P < 0.05$, $P < 0.001$).

**Discussion**

In recent years, polypeptides have been a hot topic in research. Polypeptides have been applied in many fields as therapeutics and biomarkers and in the vaccine field.\textsuperscript{32} A review published in 2020 suggested that polypeptides may be anti-infective drugs against different pathogens with potential biotechnological applications.\textsuperscript{38} Studies on diabetes and polypeptides have reported that the effect of diabetes drugs and polypeptides in vivo is therapeutic, but the specific mechanism remains unclear; another study indicated that glucagon-like peptide-1 (GLP-1) stimulates insulin secretion, which plays a role in type 2 diabetes.\textsuperscript{34,35} Moreover an in vitro model suggested that GLP-1 improves the function of endothelial nitric oxide synthase (eNOS) to prevent or delay the formation of atherosclerosis in diabetes mellitus; study in Human umbilical vascular endothelial cells (HUVECs) showed that GLP-1 promotes angiogenesis.\textsuperscript{36,37} The polypeptide ELABELA has become a research focus in many fields.
(hypertension, CVD, renal disease, thyroid gland disease and PE) in recent years, and the latest progress has supported and highlighted its therapeutic potential\(^3\),\(^8\). There is still a lack of research on the peptide COL-4A1 and PE, thus the current study is focused on exploring the association between COL-4A1 and PE (Supplementary Information).

Shallow placental implantation and insufficient remodelling uterine spiral artery have been recognized as pathologies of PE for many years. Our results are consistent with this conclusion. From our above results, we know that in vivo, the model rats showed PE-like symptoms: increased blood pressure, FGR, and placenta and kidney abnormalities. In vitro, COL-4A1 could inhibit proliferation, migration and tube formation and caused an increase in ROS and adhesive capacity. A review published in Hypertension suggests that the pathology of PE includes inflammation and immunological factors, but oxidative stress and imbalance between angiogenic and antiangiogenic factors are also important pathological mechanisms that cause PE\(^4\). Compared to cells without COL-4A1 treatment, cells treated with COL-4A1 showed elevated VEGF mRNA expression and decreased PIGF expression through the results of qRT-PCR. Additionally, through ROS and adhesion assays, we discovered that cells treated with COL-4A1 had elevated ROS levels and an increased adhesive capacity. These results are consistent with the vascular endothelial damage theory\(^1\). When vascular endothelial cells are damaged, proinflammatory factors are expressed, angiogenic and antiangiogenic factors become unbalanced, ROS are produced, and the capacity to adhere is elevated.

The TGF-β and PI3K/AKT signalling pathways are common to PE and play key roles in many cellular processes, such as proliferation, migration, apoptosis, and angiogenesis\(^2\),\(^3\),\(^4\),\(^5\). In recent years, many researches on TGF-β has been carried out. TGF-β signalling has been reported to be dysregulated in early-onset severe PE\(^6\). The TGF-β signalling pathway includes the Smad-dependent pathway and Smad-independent pathway, which contains the PI3K/AKT pathway. Furthermore, studies have suggested that TGF-β/PI3K/AKT is related to cell migration\(^6\),\(^7\). Additionally, some reviews have reported that PI3K/AKT, which may contribute to the pathology of PE, plays key roles in cell metabolism, proliferation, the inhibition of tube formation and the mediation of inflammatory processes\(^7\),\(^8\). The results of a 2019 bioinformatics analysis suggested that the TGF-β signalling pathway inhibited HTR-8/SVneo cell and HUVECs proliferation, migration, invasion and tube formation\(^9\). However, the correlation between the TGF-β superfamily and PE is complex\(^3\),\(^4\),\(^5\). In 2006, a study suggested that PE impaired TGF-β1 pathway, and decreased the amount of TGF-β1\(^1\). However, another study demonstrated that the levels of plasma TGF-β1 and TGF-β2 are elevated in PE\(^1\). Based on our RNA sequencing and mass spectrometry analysis results, we further performed WB assays. Based on the results of our WB assays, the protein expression of TGF-β was decreased (\(P < 0.01\)), but PI3K expression and the p-AKT/AKT ratio were increased. We considered that COL-4A1 may function through targeting the TGF-β pathway, decreasing TGF-β, activating the PI3K/AKT pathway and eventually causing PE.

**Figure 5.** Differences in protein levels between the control and biotin COL-4A1 groups, as determined by pull-down assays, mass spectrometry and WB assays. (A) SDS-PAGE following pull-down assays with each group; the gels underwent silver staining. Differential protein fragments are marked with a red box. (B) Venn diagram. (C) Pathway analysis. (D, E) Western blotting (WB) analysis of antibodies (TGF-β, PI3K, p-AKT and AKT) in the control and COL-4A1 groups. (\(^*\) \(P < 0.05\), \(^**\) \(P < 0.01\), \(^***\) \(P < 0.001\)).
The strengths of this study includes not only in vivo animal experiments but also in vitro cell experiments. Further this is the first study to study the correlation between polypeptide COL-4A1 and PE. In summary, the present study highlights the correlation between COL-4A1 and PE, as the COL-4A1 peptide caused PE-like symptoms by inhibiting cell proliferation and migration. COL-4A1 may function through the TGF-β/PI3K/AKT pathway. Therefore, this research provides a basis for the pathogenesis of PE and provides a promising potential target for treatment.

Received: 15 December 2020; Accepted: 13 July 2021
Published online: 03 August 2021

References
1. Han, C., Huang, P., Lyu, M. & Dong, J. Oxidative stress and preeclampsia-associated prothrombotic state. Antioxidants (Basel, Switzerland). 9(11), 1139 (2020).
2. Michalczzyk, M., Clewicz, A., Clewicz, M., Woźniakowska-Gondek, P. & Rzepka, R. The role of inflammation in the pathogenesis of preeclampsia. Mediat. Inflamm. 2020, 3864941 (2020).
3. Mol, B. W. J. et al. Pre-eclampsia. Lancet (London, England). 387(10022), 999–1011 (2016).
4. Vika, B. E., Ingens, L. M., Leivestad, T., Skjærvest, R. & Iversen, B. M. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 359(8), 800–809 (2008).
5. Ahmed, R., Dunford, J., Mehran, R., Robson, S. & Kundan, V. Pre-eclampsia and future cardiovascular risk among women: A review. J. Am. Coll. Cardiol. 63(18), 1815–1822 (2014).
6. Al-Nasiry, S. Metabolic syndrome after pregnancies complicated by pre-eclampsia or small-for-gestational-age: A retrospective cohort. BJOG Int. J. Obstet. Gynecol. 122(13), 1818–1823 (2015).
7. Veerbeek, J. H. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension (Dallas, Tex.: 1979). 65(3), 600–606 (2015).
8. Say, L. et al. Global causes of maternal death: A WHO systematic analysis. Lancet Glob. Health 2(6), e323–e333 (2014).
9. Huang, J. et al. Overexpression of long noncoding RNA Uc.187 induces preeclampsia-like symptoms in pregnancy rats. Am. J. Hypertens. 33(5), 439–451 (2020).
10. Jebbink, J. et al. Molecular genetics of preeclampsia and HELLP syndrome—A review. Biochem. Biophys. Acta. 1822(12), 1960–1969 (2012).
11. Rana, S., Karumanchi, S. A. & Lindheimer, M. D. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (Dallas, Tex.: 1979). 62(3), 198–202 (2014).
12. Ali, S. M. & Khalil, R. A. Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy. Expert Opin. Ther. Targets 19(11), 1495–1515 (2015).
13. Staff, A. C. The two-stage placental model of preeclampsia: An update. J. Reprod. Immunol. 134–135, 1–10 (2019).
14. Rana, S., Lemoine, E., Granger, J. P. & Karumanchi, S. A. Preeclampsia: Pathophysiology, challenges, and perspectives. Circ. Res. 124(7), 1094–1112 (2019).
15. Jim, B. & Karumanchi, S. A. Preeclampsia: Pathogenesis, prevention, and long-term complications. Semin. Nephrol. 37(4), 386–397 (2017).
16. Phipps, E., Prasanna, D., Brima, W. & Jim, B. Preeclampsia: Updates in pathogenesis, definitions, and guidelines. Clin. J. Am. Soc. Nephrol. CJASN. 11(6), 1102–1113 (2016).
17. Karumanchi, S. A. & Granger, J. P. Preeclampsia and pregnancy-related hypertension disorders. Hypertension (Dallas, Tex.: 1979). 67(2), 238–242 (2016).
18. Gilbert, J. S. et al. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 294(2), H541–H550 (2008).
19. Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672–683 (2004).
20. Dai, X. et al. Peptide analysis of human serum from normal and preeclamptic pregnant women. J. Cell. Biochem. 118(12), 4341–4348 (2017).
21. Fazleabas, A. T., Bell, S. C., Fleming, S., Sun, J. & Lessey, B. A. Distribution of integrins and the extracellular matrix proteins in the baboon endometrium during the menstrual cycle and early pregnancy. Biol. Reprod. 56(2), 348–356 (1997).
22. Pfarrer, C., Hirsch, P., Guillemot, M. & Leiser, R. Interaction of integrin receptors with extracellular matrix is involved in trophoblast giant cell migration in bovine placentomes. Placenta 26(6), 856–857 (2003).
23. Wang, H. & Su, Y. Collagen IV contributes to nitric oxide-induced angiogenesis of lung endothelial cells. Am. J. Physiol. Cell Physiol. 300(5), C979–C988 (2011).
24. Wang, F. et al. T7 peptide inhibits angiogenesis via downregulation of angiopeptin-2 and autophagy. Oncol. Rep. 33(2), 675–684 (2015).
25. Preil, S. A. et al. Quantitative proteome analysis reveals increased content of basement membrane proteins in arteries from patients with type 2 diabetes mellitus and lower levels among metformin users. Circ. Cardiovasc. Genet. 8(5), 727–735 (2015).
26. Steffensen, L. B. & Rasmussen, L. M. A role for collagen type IV in cardiovascular disease?. Am. J. Physiol. Heart Circ. Physiol. 315(3), H610–H625 (2018).
27. Park, J. K. et al. Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro. Placenta 33(7), 621–629 (2012).
28. Li, X. et al. Cys-peptide mediates the protective role in preeclampsia-like rat and cell models. Life Sci. 251, 117625 (2020).
29. Silver, N., Best, S., Jiang, J. & Thein, S. L. Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol. Biol. 7, 33 (2006).
30. Wu, K., Liu, F., Wu, W., Chen, Y. & Zhang, W. Bioinformatics approach reveals the critical role of TGF-β signaling pathway in pre-eclampsia development. Eur. J. Obstet. Gynecol. Reprod. Biol. 240, 130–138 (2019).
31. Hemmings, B. A. & Restuccia, D. F. PI3K-PKB/Akt pathway. Cold Spring Harb. Perspect. Biol. 4(9), a011899 (2012).
32. Fosgerau, K. & Hoffmann, T. Peptide therapeutics: Current status and future directions. Drug Discov. Today 20(1), 122–128 (2015).
33. de Freire Bastos, M. D. C., Miceli de Farias, F., Carlin Fagundes, P. & Varella Coelho, M. L. Staphylococcins: An update on antimicrobial peptides produced by staphylococci and their diverse potential applications. Appl. Microbiol. Biotechnol. 104(24), 10339–10368 (2020).
34. Quintiliano, D. L. et al. Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide. Naunyn-Schmiedebergs Arch. Pharmacol. 394, 697–705 (2020).
35. Xu, J., Zheng, T., Zhao, C., Huang, X. & Du, W. Resistance of neptep and its analogs on the fibril formation of human islet amyloid polypeptide. Int. J. Biol. Macromol. 166, 435–447 (2020).
36. Ding, L. & Zhang, J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin. 33(1), 75–81 (2012).
37. Aronis, K. N., Chamberland, J. P. & Mantzoros, C. S. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. *Metab. Clin. Exp.* **62**(9), 1279–1286 (2013).

38. Bankir, M., Abayli, C. & Acibucu, F. Importance of ELABELA in the differential diagnosis of benign and malignant lesions of the thyroid gland. *Arch. Endocrinol. Metab.* **64**, 772–778 (2020).

39. Xu, C. The Elabela in hypertension, cardiovascular disease, renal disease, and preeclampsia: An update. *J. Hypertens.* **39**, 12–22 (2020).

40. Phipps, E. A., Thadhani, R., Benzing, T. & Karumanchi, S. A. Pre-eclampsia: Pathogenesis, novel diagnostics and therapies. *Nat. Rev. Nephrol.* **15**(5), 275–289 (2019).

41. Song, J. & Landström, M. TGFβ activates PI3K-AKT signaling via TRAF6. *Oncotarget* **8**(59), 99205–99206 (2017).

42. Hamidi, A. et al. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitination of p65α. *Sci. Signal.* **10**(486), eaal4186 (2017).

43. Jia, Y., Xie, H., Zhang, J. & Ying, H. Induction of TGF-β receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia. *FASEB J.* **34**, 13224–13238 (2020).

44. Perucci, L. O. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. *PLoS One.* **9**(5), e97632 (2014).

Acknowledgements

This research was financially supported by the National Natural Science Foundation of China (81801470, 81771604), State Key Laboratory of Reproductive Medicine (SKLRM-UC201901).

Author contributions

T.L., Z.L.: Study & experimental design, experimental operation, statistical analysis, manuscript writing. C.L., H.D.: Study & experimental design, manuscript editing & reviewing, funding support. K.X.: Study & experimental design, statistical analysis, manuscript editing & reviewing. Y.W., Z.M., X.J.: Study & experimental design, experimental operation. J.L., W.H., Q.T., X.Y., N.L.: Study & experimental design, statistical analysis.

Competing interests

All authors state that they have no conflicts of interest. We confirm the study was carried out in compliance with the ARRIVE guidelines (http://www.nc3rs.org.uk/page.asp?id=1357).

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-94801-5.

Correspondence and requests for materials should be addressed to C.L. or H.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021